Sernova Biotherapeutics Inc
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Jonathan M. N. Rigby
- Full Time Employees
- 8
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- RPO Central Parkway Mississauga ON Canada L5A 4H2
- IPO Date
- Apr 29, 1999
- Website
- sernova.com
- Similar Companies
- Business
- Sernova Corp is a clinical-stage biotechnology company headquartered in London, Ontario, Canada, specializing in regenerative medicine therapeutics focused on treating chronic diseases including insulin-dependent diabetes (type 1 diabetes), thyroid disorders, and blood disorders such as hemophilia A. The company develops and commercializes its core product, the Cell Pouch System, an implantable and scalable bio-hybrid organ device designed to create an immune-protected environment for therapeutic cells to produce and release essential hormones and proteins missing or deficient in patients due to chronic disease. Sernova’s therapeutic offerings combine the Cell Pouch with human donor cells or stem-cell-derived islet-like clusters, aiming to restore normal organ function and provide a functional cure for chronic conditions. Founded in 2006, Sernova operates primarily in Canada and targets patients with metabolic diseases that require replacement of critical hormones or proteins. The company’s pipeline focuses on regenerative therapies that address the underlying causes of type 1 diabetes and other hormone deficiency-related chronic conditions. Sernova’s technology platform fosters improved cell survival and function by replicating an organ-like microenvironment, which has shown promising safety and early efficacy results in ongoing clinical trials. In recent developments, Sernova has advanced its clinical program with the launch of Cohort C in its Phase I/II clinical trial, incorporating tegoprubart, a novel investigational immunomodulatory antibody, replacing the existing tacrolimus standard of care to enhance therapeutic outcomes related to islet cell engraftment, survival, and function. In November 2025, the company closed the first tranche of a private placement raising CAD $874,600, alongside a significant CAD $13.8 million legacy debt-to-equity conversion, strengthening its financial position to support further clinical development. Sernova also collaborates with Evotec to enhance its bio-hybrid organ technologies and actively seeks strategic partnerships to expand its regenerative medicine platform. Sernova’s leadership includes CEO Jonathan Rigby, who joined in 2024, guiding the company through its clinical advancement and strategic financing initiatives. The company is publicly traded on the Toronto Stock Exchange under the ticker symbol SVA.TO, emphasizing its commitment to pioneering regenerative medicine solutions with multibillion-dollar market potential for type 1 diabetes and other chronic disease indications.
Company News
Sernova and Seraxis Close US$11.2 Million Financing to Fund Merger to Become BetaNova Biotherapeutics and Advance Type 1 Diabetes Cell Therapy Into Near Term Phase 1/2 Clinical Trial
Sernova Biotherapeutics to Participate in Noble Capital Markets' Emerging Growth Virtual Equity Conference
Sernova Biotherapeutics Announces Closing of Recently Approved Financings
Sernova Biotherapeutics Announces Affirmative Voting Results from 2026 Annual General Meeting of Shareholders
Sernova Biotherapeutics Announces Close of Non-Brokered Private Placement Financing
Sernova Biotherapeutics Strengthens Balance Sheet with $7.1 Million in Financings Plus Net Retirement of a Cumulative $17 Million of Debt Subject to Shareholder Approval
Sernova Biotherapeutics Announces Warrant Amendments
Sernova Biotherapeutics Announces $13 Million Debt-to-Equity Conversion Eliminating Significant Financing Overhang
Sernova Biotherapeutics Appoints John L. Brooks III, Former Chair and CEO of Joslin Diabetes Research Center, as Chair of the Board of Directors
Sernova Biotherapeutics Announces Collaboration with Eledon Pharmaceuticals to Advance a Potential Functional Cure for Type 1 Diabetes
Sernova Appoints Jonathan Rigby as Interim Chair
Chair of Sernova Biotherapeutics Resigns
Sernova Biotherapeutics Appoints World-Class Clinical Advisory Board to Support Development of Cell Pouch Bio-hybrid Organ as Functional Cure for Type 1 Diabetes
Sernova Biotherapeutics Provides Positive Interim Data from Ongoing Phase 1/2 Clinical Trial of Cell Pouch Bio-hybrid Organ in Patients Living with Type 1 Diabetes
Sernova Biotherapeutics Secures $4 Million Loan to Further Advance its Clinical Development Plans
Sernova Biotherapeutics Cell Pouch Bio-hybrid Organ to be Highlighted at Cell & Gene Meeting on the Med
Sernova Biotherapeutics Provides Update on Phase 1/2 Clinical Trial of Cell Pouch™ Bio-Hybrid Organ for Treatment of Type 1 Diabetes
Sernova Biotherapeutics Appoints Pericles Calias, Ph.D. as Chief Development Officer and Head of R&D
Sernova Biotherapeutics Secures $1 Million Convertible Debt Financing
Sernova Biotherapeutics Receives FDA Clearance for IND Application for its Cell Pouch Bio-hybrid Organ with Autograft Thyroid Cells in Patients with Hypothyroidism